Latest stories on PCVX
Vaxcyte Has $2.5 Billion in Cash and a $605 Million Half-Year Loss. Here's How to Read Its CFO's Latest Insider Filing
Yahoo Finance48 · neutralgeneral
A Vaxcyte Executive Just Cashed Options Struck at $5.35. Here's What Long-Term Investors Should Know
Yahoo Finance50 · neutralgeneral
Vaxcyte's CEO Parted With Shares for Taxes. Here's What Long-Term Investors Should Know About the Firm
Yahoo Finance53 · neutralgeneral
Vaxcyte Has $2.5 Billion in Cash and a $605 Million Half-Year Loss. Here's How to Read Its CFO's Latest Insider Filing
The Motley Fool48 · neutralgeneral
A Vaxcyte Executive Just Cashed Options Struck at $5.35. Here's What Long-Term Investors Should Know
The Motley Fool50 · neutralgeneral
Vaxcyte's CEO Parted With Shares for Taxes. Here's What Long-Term Investors Should Know About the Firm
The Motley Fool52 · neutralgeneral
Vaxcyte narrows timing for pivotal VAX-31 data to late October
Seeking Alpha67 · bullishproduct/pr
The Next Year Will Define Vaxcyte’s (PCVX) Vaccine Gamble
Yahoo Top52 · neutralgeneral
Vaxcyte names Luis Jodar chief medical officer, David McAvoy chief legal officer
The Fly55 · neutralgeneral
Vaxcyte narrows previously communicated VAX-31 guidance
The Fly56 · neutralearnings
Vaxcyte, Inc. (PCVX) files 8-K
SEC 8-K50 · neutralgeneral
Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data
Business Insider56 · neutralgeneral
Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data
GlobeNewswire42 · neutralgeneral
Vaxcyte to Participate in Upcoming Investor Conferences
Business Insider56 · neutralgeneral
Vaxcyte to Participate in Upcoming Investor Conferences
GlobeNewswire56 · neutralgeneral
Vaxcyte: Not Enough Safety Margin With Current Price
Seeking Alpha38 · neutralanalyst
If You Followed Seth Klarman Into Vaxcyte in May, He Was Already Long Gone
Yahoo Top38 · neutralgeneral
Vaxcyte, Inc. (PCVX) files 8-K
SEC 8-K50 · neutralgeneral
Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update
Business Insider55 · neutralgeneral
Vaxcyte: Clinical-Stage Vaccine Disrupter With Vast Near-Term Potential
Seeking Alpha67 · bullishproduct/pr
Vaxcyte, Inc. (PCVX) files 8-K
SEC 8-K50 · neutralgeneral
Vaxcyte to Participate in Upcoming Investor Conferences
Business Insider56 · neutralgeneral
Vaxcyte to Participate in Upcoming Investor Conferences | PCVX Stock News
StockTitan56 · neutralgeneral
Vaxcyte Inc (PCVX) Is A Hidden Multibagger Stock To Buy Now
Yahoo Finance67 · bullishanalyst
Vaxcyte Announces Board Transition and New Director Appointment
TipRanks50 · neutralgeneral